Mounjaro may not be appropriate for: Individuals with a personal or family history of medullary thyroid carcinoma (MTC) Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Those with known hypersensitivity to Tirzepatide or any component of the formulation This is not an exhaustive list
Always check the expiration date or beyond-use-date (BUD) before administering the medication and analyze the injection
Hydration and Nutrition GLP-1 medications can reduce your thirst cues
Tirzepatide offers cardiovascular protection (38% reduction in heart failure events), liver fat reduction and MASH resolution (44-62% of patients), sleep apnea improvement (up to 63% AHI reduction), blood pressure reduction (up to 5.8 mmHg), cholesterol improvement (24.9% triglyceride reduction), kidney protection (33% fewer major kidney events), joint pain reduction, PCOS symptom improvement, and systemic inflammation reduction
ADA adds mental health, GLP-1 questions to health history forms Course prepares dental professionals to identify issues during updates, refer patients for help Updated patient health history forms from the American Dental Association include a new screening question related to mental health and the addition of GLP-1 receptor agonists to the list of medications patients may be taking